Abstract
The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:New Oral Anticoagulants in Coronary Artery Disease
Volume: 15 Issue: 2
Author(s): Michael Behnes, Christian Fastner, Uzair Ansari and Ibrahim Akin
Affiliation:
Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.
Abstract: The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
Export Options
About this article
Cite this article as:
Behnes Michael, Fastner Christian, Ansari Uzair and Akin Ibrahim, New Oral Anticoagulants in Coronary Artery Disease, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209111429
DOI https://dx.doi.org/10.2174/1871529X1502151209111429 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews The Impact of Metabolic Disease Associated with Metabolic Syndrome on Human Pregnancy
Current Pharmaceutical Biotechnology Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design The Causal Relationship Between Passive Smoking and Inflammation on the Development of Cardiovascular Disease: A Review of the Evidence
Inflammation & Allergy - Drug Targets (Discontinued) Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design Triglyceride Level Affecting Shared Susceptibility Genes in Metabolic Syndrome and Coronary Artery Disease
Current Medicinal Chemistry Atypical Neurotransmitters and the Neurobiology of Depression
CNS & Neurological Disorders - Drug Targets Antimicrobial and Biofilm Inhibiting Diketopiperazines
Current Medicinal Chemistry Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]
Current Alzheimer Research Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Definitions of Metabolic Syndrome: Where are We Now?
Current Vascular Pharmacology Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews